4.5 Review

What do I need to know about immunoglobulin light chain (AL) amyloidosis?

Journal

BLOOD REVIEWS
Volume 26, Issue 4, Pages 137-154

Publisher

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2012.03.001

Keywords

Amyloidosis; Multisystem disease; Monoclonal gammopathy; Prognosis; Transplantation

Categories

Funding

  1. Celgene
  2. Millenium
  3. JABBS Foundation
  4. Predolin Foundation
  5. National Cancer Institute [CA125614, CA107476]

Ask authors/readers for more resources

Immunoglobulin light chain (AL) amyloidosis is the most common acquired systemic amyloidoses. Its presentation is often insidious and progressive, which may delay diagnosis. The interval between first symptoms and actual diagnosis along the intrinsic heterogeneity of tissue tropism create a wide spectrum of presentations, both in terms of scope and depth of symptoms and signs and functional status of patients. In this review, the authors review the pathogenesis, diagnosis and differential diagnosis of AL amyloidosis along with the prognosis and state-of-the-art management for patients with this affliction. (C) 2012 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available